Prevalence of Carbapenem-Resistant Klebsiella pneumoniae Infection in a Northern Province in China: Clinical Characteristics, Drug Resistance, and Geographic Distribution

References

• Zhu J, Wang T, Chen L, Du H. Virulence factors in hypervirulent Klebsiella pneumoniae. Front Microbiol. 2021;12:642484. doi:10.3389/fmicb.2021.642484
   PubMed Web of Science ®Google Scholar
• Martin RM, Bachman MA. Colonization, Infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. doi:10.3389/fcimb.2018.00004
   PubMed Web of Science ®Google Scholar
• Di Tella D, Tamburro M, Guerrizio G, Fanelli I, Sammarco ML, Ripabelli G. Molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical Klebsiella pneumoniae isolates. Infect Drug Resist. 2019;12:3783–3795. doi:10.2147/IDR.S226416
   PubMed Web of Science ®Google Scholar
• Guh AY, Limbago BM, Kallen AJ. Epidemiology and prevention of carbapenem-resistant Enterobacteriaceae in the United States. Expert Rev Anti Infect Ther. 2014;12(5):565–580. doi:10.1586/14787210.2014.902306
   PubMed Web of Science ®Google Scholar
• Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151–1161. doi:10.1128/AAC.45.4.1151-1161.2001
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
   PubMed Web of Science ®Google Scholar
• Barbadoro P, Dichiara A, Arsego D, et al. Spread of carbapenem-resistant Klebsiella pneumoniae in hub and spoke connected health-care networks: a case study from Italy. Microorganisms. 2019;8(1):37. doi:10.3390/microorganisms8010037
   Web of Science ®Google Scholar
• Diallo OO, Baron SA, Abat C, Colson P, Chaudet H, Rolain JM. Antibiotic resistance surveillance systems: a review. J Glob Antimicrob Resist. 2020;23:430–438. doi:10.1016/j.jgar.2020.10.009
   PubMed Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106. doi:10.1086/592412
   PubMed Web of Science ®Google Scholar
• Grundmann H, Glasner C, Albiger B, et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17(2):153–163. doi:10.1016/S1473-3099(16)30257-2
   PubMed Web of Science ®Google Scholar
• Zhang R, Chan EW, Zhou H, Chen S. Prevalence and genetic characteristics of carbapenem-resistant Enterobacteriaceae strains in China. Lancet Infect Dis. 2017;17(3):256–257. doi:10.1016/S1473-3099(17)30072-5
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang J, Fu Y, et al. Synergetic effects of combined treatment of colistin with meropenem or amikacin on carbapenem-resistant Klebsiella pneumoniae in vitro. Front Cell Infect Microbiol. 2019;9:422. doi:10.3389/fcimb.2019.00422
   Web of Science ®Google Scholar
• Liao W, Liu Y, Zhang W. Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years. J Glob Antimicrob Resist. 2020;23:174–180. doi:10.1016/j.jgar.2020.09.004
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi Q, Hu H, et al. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China. Clin Microb Infect. 2020;26(1):124.e121–124.e124. doi:10.1016/j.cmi.2019.08.020
   Web of Science ®Google Scholar
• Matsumoto S, Singley CM, Hoover J, et al. Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob Agents Chemother. 2017;61(9). doi:10.1128/AAC.00700-17.
   Web of Science ®Google Scholar
• Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9(1):79. doi:10.1186/s13756-020-00728-3
   Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707. doi:10.1128/CMR.05035-11
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791–1798. doi:10.3201/eid1710.110655
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol. 2019;17(5):295–306. doi:10.1038/s41579-019-0159-8
   PubMed Web of Science ®Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–458, table of contents. doi:10.1128/CMR.00001-07
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu C, Shen Z, et al. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018. Emerg Microbes Infect. 2020;9(1):1771–1779. doi:10.1080/22221751.2020.1799721
   PubMed Web of Science ®Google Scholar
• Rojas LJ, Salim M, Cober E, et al. Colistin resistance in carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clin Infect Dis. 2017;64(6):711–718. doi:10.1093/cid/ciw805
   PubMed Web of Science ®Google Scholar
• Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13(9):785–796. doi:10.1016/S1473-3099(13)70190-7
   PubMed Web of Science ®Google Scholar
• Malinga NZZ, Shobo CO, Molechan C, Amoako DG, Zishiri OT, Bester LA. Molecular surveillance and dissemination of Klebsiella pneumoniae on frequently encountered surfaces in South African Public Hospitals. Microb Drug Resist. 2021. doi:10.1089/mdr.2020.0546
   Web of Science ®Google Scholar
• Gao L, Lv Y, Li Y. Analysis of the drug resistance of carbapenem-resistant Klebsiella pneumoniae in the China antimicrobial resistance surveillance trial program, 2007–2018. Microb Drug Resist. 2020;26(8):944–950. doi:10.1089/mdr.2019.0299
   PubMed Web of Science ®Google Scholar
• Park SO, Liu J, Furuya EY, Larson EL. Carbapenem-resistant Klebsiella pneumoniae infection in three New York City Hospitals Trended downwards from 2006 to 2014. Open Forum Infect Dis. 2016;3(4):ofw222. doi:10.1093/ofid/ofw222
   Google Scholar
• Hu F, Zhu D, Wang F, Wang M. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl_2):S128–s134. doi:10.1093/cid/ciy657
   PubMed Web of Science ®Google Scholar
• Chuang C, Su CF, Lin JC, et al. Does antimicrobial therapy affect mortality of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria? A nationwide multicenter study in Taiwan. Microorganisms. 2020;8(12):2035. doi:10.3390/microorganisms8122035
   PubMed Web of Science ®Google Scholar
• Li J, Li Y, Song N, Chen Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis. J Glob Antimicrob Resist. 2020;21:306–313. doi:10.1016/j.jgar.2019.09.006
   PubMed Web of Science ®Google Scholar
• El-Badawy MF, El-Far SW, Althobaiti SS, Abou-Elazm FI, Shohayeb MM. The First Egyptian report showing the co-existence of bla (NDM-25), bla (OXA-23), bla (OXA-181), and bla (GES-1) among carbapenem-resistant K. pneumoniae clinical isolates genotyped by BOX-PCR. Infect Drug Resist. 2020;13:1237–1250. doi:10.2147/IDR.S244064
   Web of Science ®Google Scholar
• Zhang R, Dong N, Huang Y, et al. Evolution of tigecycline- and colistin-resistant CRKP (carbapenem-resistant Klebsiella pneumoniae) in vivo and its persistence in the GI tract. Emerg Microbes Infect. 2018;7(1):127. doi:10.1038/s41426-018-0129-7
   PubMed Web of Science ®Google Scholar
• Horita N, Shibata Y, Watanabe H, Namkoong H, Kaneko T. Comparison of antipseudomonal β-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis. Clin Microb Infect. 2017;23(10):723–729. doi:10.1016/j.cmi.2017.03.024
   Web of Science ®Google Scholar
• Nimmich EB, Bookstaver PB, Kohn J, et al. Development of institutional guidelines for management of gram-negative bloodstream infections: incorporating local evidence. Hosp Pharm. 2017;52(10):691–697. doi:10.1177/0018578717720506
   Google Scholar
• Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother. 2011;55(2):593–599. doi:10.1128/AAC.01020-10
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/CMR.00079-17
   PubMed Web of Science ®Google Scholar
• Hou SY, Wu D, Feng XH. Polymyxin monotherapy versus polymyxin-based combination therapy against carbapenem-resistant Klebsiella pneumoniae: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2020;23:197–202. doi:10.1016/j.jgar.2020.08.024
   PubMed Web of Science ®Google Scholar
• Peterson LR. A review of tigecycline–the first glycylcycline. Int J Antimicrob Agents. 2008;32(Suppl 4):S215–222. doi:10.1016/S0924-8579(09)70005-6
   PubMed Web of Science ®Google Scholar
• Ni W, Han Y, Liu J, et al. Tigecycline treatment for carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Medicine. 2016;95(11):e3126. doi:10.1097/MD.0000000000003126
   PubMed Web of Science ®Google Scholar
• An X, Xie W, Zheng X, Zhao L, Wu Y, Qu Y. [Detection and analysis of carbapenem-resistant Klebsiella pneumoniae resistance genes in five hospitals in Qingdao City]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32(2):145–149. Chinese. doi:10.3760/cma.j.cn121430-20200110-00027
   Google Scholar
• Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(3):905–913. doi:10.1093/jac/dku432
   PubMed Web of Science ®Google Scholar
• van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(4):1203–1211. doi:10.1093/jac/dku495
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55(12):5893–5899. doi:10.1128/AAC.00387-11
   PubMed Web of Science ®Google Scholar
• He G, Huang J, Huang S, et al. Risk factors affecting clinical outcome in patients with carbapenem-resistant K. pneumoniae: a retrospective study. Med Sci Monitor. 2020;26:e925693. doi:10.12659/MSM.925693
   Web of Science ®Google Scholar
• Lombardi F, Gaia P, Valaperta R, et al. Emergence of carbapenem-resistant Klebsiella pneumoniae: progressive spread and four-year period of observation in a cardiac surgery division. Biomed Res Int. 2015;2015:871947. doi:10.1155/2015/871947
   PubMed Web of Science ®Google Scholar
• Su J, Li D, Guo Q, Guo Y, Zheng Y, Xu X. In vitro bactericidal activity of trimethoprim-sulfamethoxazole/colistin combination against carbapenem-resistant Klebsiella pneumoniae clinical isolates. Microb Drug Resist. 2019;25(2):152–156. doi:10.1089/mdr.2018.0085
   Web of Science ®Google Scholar
• Gagliotti C, Giordani S, Ciccarese V, et al. Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study. Am J Infect Control. 2014;42(9):1006–1008. doi:10.1016/j.ajic.2014.05.028
   Web of Science ®Google Scholar
• Lee SO, Kim NJ, Choi SH, et al. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother. 2004;48(1):224–228. doi:10.1128/AAC.48.1.224-228.2004
   Web of Science ®Google Scholar
• Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41(3):252–275. doi:10.1093/femsre/fux013
   PubMed Web of Science ®Google Scholar